Logo
x

Search

Subscribe Now

Dravet Syndrome

Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Caregivers- and Families at AAN 2021

Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Care...

  • April 19, 2021
Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

  • March 4, 2021
PharmaShots Interview: Zogenix's Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

PharmaShots Interview: Zogenix's Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

  • February 16, 2021
Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome

Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome

  • August 26, 2020
Zogenix Reports the US FDA Acceptance of NDA and Granted Priority Review for Fintepla (fenfluramine) to Treat Dravet Syndrome

Zogenix Reports the US FDA Acceptance of NDA and Granted Priority Review for Fintepla (fenfluramine) to Treat Dravet Syndrome

  • November 26, 2019
Stoke Therapeutics' STK-001 Receives FDA's Orphan Drug Designation for Dravet Syndrome

Stoke Therapeutics' STK-001 Receives FDA's Orphan Drug Designation for Dravet Syndrome

  • August 8, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.